HYBRID EVENT: You can participate in person at London, UK or Virtually from your home or work.

5th Edition of Euro-Global Conference on Biotechnology and Bioengineering

September 18-20 | Hybrid Event

September 18-20, 2025 | London, UK

Polyploidy

Polyploidy

Polyploidy is a genetic condition characterized by the presence of multiple sets of chromosomes within an organism's cells, in contrast to the typical diploid state. This phenomenon can result from errors in cell division, leading to an increase in the number of chromosome sets. It plays a crucial role in evolution by providing genetic diversity, enabling adaptation to various environmental conditions. Autopolyploidy involves duplication of the same genome, while allopolyploidy results from the combination of different genomes. Polyploid organisms often exhibit altered characteristics, such as increased vigor, larger size, and enhanced adaptability, making them significant subjects of study in genetics and evolutionary biology. Researchers explore the implications of polyploidy in agriculture, as it can influence crop improvement, disease resistance, and overall plant performance.

Committee Members
Speaker at Biotechnology and Bioengineering 2025 - Thomas J Webster

Thomas J Webster

Interstellar Therapeutics, United States
Speaker at Biotechnology and Bioengineering 2025 - Steve Busby

Steve Busby

University of Birmingham, United Kingdom
Speaker at Biotechnology and Bioengineering 2025 - Murray Moo Young

Murray Moo Young

University of Waterloo, Canada
ECBB 2025 Speakers
Speaker at Biotechnology and Bioengineering 2025 - Julia Sidorova

Julia Sidorova

Centro de Investigación Biomédica En Red Enfermedades Hepáticas y Digestivas (CIBEREHD), Spain
Speaker at Biotechnology and Bioengineering 2025 - Luis Jesus Villarreal Gomez

Luis Jesus Villarreal Gomez

Universidad Autonoma de Baja California, Mexico
Speaker at Biotechnology and Bioengineering 2025 - Assad Al Ammar

Assad Al Ammar

Specialty Enzymes and Probiotics, United States
Speaker at Biotechnology and Bioengineering 2025 - Tina Moller Tagmose

Tina Moller Tagmose

Novo Nordisk A/S, Denmark

Submit your abstract Today

Watsapp
a